Divi's Laboratories jumped 3.6% in intraday trade today after US-based pharmaceutical major Merck announced a supply agreement with the US government for the experimental Covid-19 drug, Molnupiravir.
As per the agreement, Merck, also known as MSD outside the United States and Canada, will procure the drug for the United States government and Divi's Laboratories will supply the active pharmaceutical ingredient (API) for the drug.
On 26 May 2021, Divi's Laboratories was selected by the company as an authorized manufacturer for the API of Molnupiravir.
Divi's Lab will supply the API to MSD's partners in India.
Molnupiravir is currently being evaluated in a Phase 3 clinical trial, for the treatment of non-hospitalised Covid-19 patients.
The US government has committed to purchase approximately 1.7 m courses of Molnupiravir upon issuance of emergency use authorization or approval by the U.S. Food and Drug Administration.
MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics.
--- Advertisement ---
Did You Know?
Asian Paints is Actually NOT a Paint Company
Most investors blindly believed Asian Paints to be a paint company...
..and simply lost the opportunity to make a staggering 86,237% gains over the last 3 decades. *Not an Equitymaster recommendation
If you missed it, don't worry.
Because our Co-head of Research Tanushree Banerjee has zeroed in on 20 such forever stocks that are scattered all over the market.
On June 21 at 5pm, Tanushree will be revealing the FULL details on this list at her Forever Stocks event.
If you want the opportunity to rake in Asian Paints like gains, you could register your spot here on this note...It's FREE
------------------------------
For the March 2021 quarter, Divi's Laboratories reported a 25% year on year (YoY) jump in net profit to Rs 4.9 bn against Rs 3.9 bn in the same period last year.
The company's total revenue also rose 20% YoY to Rs 17.4 bn from Rs 14.5 bn in the March 2020 quarter.
The company benefited from a low base as it was hit by the Covid-19-led national lockdown last year.
| Mar-21 | Mar-20 | YoY Change | |
|---|---|---|---|
| Revenue | 17.4 | 14.5 | 20% |
| Operating Profit | 7 | 4.5 | 55.6% |
| Net Profit | 4.9 | 3.9 | 25.6% |
The company has recently expanded capacities with an estimated investment of Rs 4 bn for fast-tracking a customs synthesis (CS) project.
A part of the project has been completed and is operational, it said, adding that the rest of the plan will be completed during the early part of the next financial year.
This unprecedented capex is an important narrative for the company as it will further augment its capacities and prepare it for growing opportunities arising from the China plus one strategy.
The impact of Divi's aggressive capex is already visible and is expected to fully reflect in 2023.
The Hyderabad-based company's board also recommended a final dividend of Rs 20 per share.
--- Advertisement ---
Watch India's Revival Special Replay
Yesterday, we went LIVE with our special event on India's Revival.
Thousands of Indians had joined us LIVE.
You too had signed up for this event. But you missed it for some reason.
No problem. We have saved the replay for you.
Click Here to Watch the Special Replay Now
Watch to get Tanushree's critical briefing on 3 revival stocks - at the heart of a mega boom - that could potentially offer around 1,000% return over the long term.
Don't miss the replay. It will go off-air very soon.
Click Here to Watch the Special Replay
------------------------------
The company's exports made up 90% of the sales for the quarter and 88% for the full fiscal.
The nutraceutical business contributed around Rs 1.6 bn to the March quarter revenue and Rs 5.9 bn to the annual revenue.
The company is operating at around 86% production capacity despite the pandemic's disruptions.
The second wave of Covid-19 has amplified logistical challenges and the company expects these challenges to continue.
However, it is confident of being able to mitigate procurement issues on account of significant investments made over past two years towards backward integration and by geographically diversifying supplier base.
Thus, it does not face any supply threats from China for raw materials.
Backward integration and constant introduction of latest technology have been key drivers for margin expansion and will continue to do so in the future.
BREAKING: It's Good Time to Invest in Gold, but Just Don't Go Blindfolded
Shares of Divi's Laboratories opened higher at Rs 4,270 on the BSE and Rs 4,275 on the NSE today.
The stock rose over 3% in intraday trade after Merck announced the signing of the supply agreement.
The scrip also touched its 52-week high of Rs 4,426.9. It had touched its 52-week low of Rs 2094.6 on 2 July 2020.
In the past six months, the stock has gained 17.3% while in the last year, it has risen by 82.8%
Divi's Laboratories is a leading manufacturer of APIs (Active pharmaceuticals ingredients), intermediates and registered starting materials in India.
The company has been established for more than thirty years in Hyderabad, India and is among the top pharmaceutical companies in the country.
It has over 14,000 highly trained professionals across departments and 350 scientists that work together to bring world-class products to customers.
The company recently reached the milestone of being one of the top 3 API manufacturers in the world and one of the top API companies in Hyderabad.
For more details about the company, you can have a look at Divi's Laboratories' factsheet and Divi's Laboratories' quarterly results on our website.
You can also compare Divi's Laboratories with its peers.
Divi's Laboratories vs Abbott India
Divi's Laboratories vs Sun Pharmaceuticals
Divi's Laboratories vs Aurobindo Pharma
To know what's moving the Indian stock markets today, check out the most recent share market updates here.
PS: We would like to welcome you to the launch of Equitymaster's newest newsletter Breakout Wealth. Our top analysts will scan the internet for the most accurate investing ideas to empower you with opinions to help you make better investment decisions. The first issue is out tomorrow! Signup for free here...
Ayesha Shetty is a financial writer with the StockSelect team at Equitymaster. An engineer by qualification, she uses her analytical skills to decode the latest developments in financial markets. This reflects in her well-researched and insightful articles. When she is not busy separating financial fact from fiction, she can be found reading about new trends in technology and international politics.
DIVIS LABORATORIES share price has hit an all time high at Rs 4,427 (up 2.2%). The BSE HEALTHCARE Index is up by 1.4%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 2.2%) and ABBOTT INDIA (up 0.5%). The top losers include SANOFI INDIA (down 0.1%) and ASTRAZENECA PHARMA (down 0.1%).
For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.
Here's a rundown on the latest quarterly results of Jubilant Pharmova.
More Views on NewsA look at the various types of primary and secondary markets and the key differences between them.
May 28, 2021There is no stopping this 11-bagger stock from significant upside.
May 28, 2021Key takeaways from Burger King India Q4FY21 results.
To become a better intraday trader, follow these rules religiously.
May 31, 2021Is the Indian central bank correct in warning you about a market crash?
More
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!